How biosimilar policy frameworks differ across major markets and what it means for prescribing

What biosimilar policy frameworks govern

Biosimilars are biologic products that have been demonstrated to be highly similar to a previously approved reference biologic, with no clinically meaningful differences in safety, purity or potency. The policy framework in each market governs:

• Approval pathway (degree of clinical comparability evidence required)
• Interchangeability designation (whether a biosimilar can be substituted by a pharmacist without prescriber involvement)
• Substitution practice (rules around switching between originator and biosimilar in patients already on therapy)
• Payer incentives (price-discounting requirements, prescriber-incentive programs, mandatory biosimilar use in certain settings)

How the major markets differ

European Union:

• Approval pathway is well-established and substantively comparable across products
• Interchangeability is generally accepted at the regulatory level, with country-by-country variation in implementation
• Substitution practice varies by country: Germany has stronger biosimilar-substitution policies than France, with Italy, Spain and the Nordics each having distinct frameworks
• Payer incentives vary; some markets (UK NHS, Germany) have aggressive biosimilar-uptake policies that drive switching at scale

United Kingdom:

• NHS-driven biosimilar policy is among the most aggressive globally, with mandatory or strongly-preferenced biosimilar use in many settings
• Interchangeability and substitution practices are well-defined and broadly accepted
• The result: biosimilar uptake rates above 90 percent in many indications within months of biosimilar entry

United States:

• Approval pathway is established but interchangeability is a more demanding regulatory standard requiring additional clinical evidence
• Substitution practice is bifurcated: indication-by-indication and state-by-state variation in substitution rules
• Payer incentives are uneven, with the buy-and-bill economics in some settings creating reverse incentives that slow biosimilar uptake
• The result: biosimilar uptake rates that are substantially lower than in major European markets in many indications

Adjacent markets (Japan, Canada, Australia, Brazil): Each has its own framework, with varying degrees of biosimilar-uptake policy aggression and varying substitution rules.

What it means for prescribing

For prescribers in any market, the policy framework determines:

• Whether biosimilar substitution happens at the pharmacy level (without prescriber involvement) or requires explicit prescriber action
• Whether switching patients already on originator therapy is encouraged, discouraged, or neutral
• Whether the prescriber's choice between originator and biosimilar is reimbursed differently
• Whether the prescriber can dispense the originator at all without specific justification

These are operational decisions that affect prescribing practice and that the framework defines materially differently across markets.

What it means for commercial planning

For sponsors of biologic classes facing biosimilar entry:

• The biosimilar dynamic is not uniform across markets. Commercial models that average across markets misrepresent the trajectory in each
• Originator strategy after biosimilar entry must be market-specific. A switch-promotion strategy that works in the US may have no traction in the UK; a defensibility strategy that works in the UK may be irrelevant in the US
• Adjacent biologic classes (newer mechanisms in the same therapeutic area) need to anticipate the framework they will face if and when biosimilar entry comes for them

For sponsors of biosimilars themselves, the framework determines launch sequencing, pricing strategy, and commercial-team structure across markets.

What we are watching

• Framework evolution in markets where biosimilar policy is being actively reshaped (US interchangeability provisions, EU framework refinements)
• Cross-market spillover effects as multinational health-system policy increasingly references biosimilar policy frameworks
• Adjacent therapeutic-area implications: as the biosimilar dynamic flows into oncology, cardiology, and other categories beyond the foundational immunology and rheumatology launches